Loading
A phase 2 trial of atezolizumab, carboplatin and etoposide in lung cancer, run by Gruppo Oncologico Italiano di Ricerca Clinica, now recruiting.
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). is a phase 2, interventional study registered as NCT06663098 by Gruppo Oncologico Italiano di Ricerca Clinica, with a registry enrolment figure of 142 participants, started 2025-01-24 and due to reach its primary completion in 2028-08-30. Interventions recorded: Atezolizumab; Carboplatin; Etoposide. Conditions listed: Extensive Stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: overall survival. Lung eligibility wording from the registry: "Diagnosis of small-cell lung cancer (SCLC) (according to WHO classification 2015) confirmed at pathology (histology or cytology)". Sites: Italy. No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads) and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Etoposide, Atezolizumab, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Atezolizumab, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Lung cancer trials open today (registry snapshot), Cytotoxic chemotherapy and the tag lung-deep-dive.
Shares Extensive-stage small-cell lung cancer, Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot) and the tag lung-deep-dive.
Shares Etoposide, Topoisomerase-I inhibitors (and ADC payloads), Lung cancer trials open today (registry snapshot), Platinum agents and the tag lung-deep-dive.